TP53 and myelodysplastic syndrome: In a recently published South American series, 18 (10%) of 182 patients with MDS harbored TP53 mutations, and five (27.7%) of these 18 were classified as bi-TP53 based on either the presence of two mutations or a VAF > 50%.